CHEK1 and acute lymphoblastic leukemia: Here, we demonstrated that our new in vitro drug schedule that combines Dox followed by ATR/CHK1 inhibitors can increase Dox cytotoxicity against ALL cells, while using lower drug doses (Fig. 6A and B).